Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.

NCT07207239•Semmelweis University

Summary

The primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS treatment. The secondary aim is to monitor the cognitive effects of TMS therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. diagnosis of depression
•2. 18 years of age
•3. Beck depression inventory score above 12 (screening)
•4. MADRS score above 6 (baseline)

Exclusion Criteria

•1. serious cognitive impairment
•2. mental retardation
•3. history of head injury with loss of consciousness for more than 1 hour
•4. alcohol or drug abuse within the past 3 months

Locations (1)

Department of Psychiatry and Psychotherapy

Budapest, Pest County, Hungary

Key Dates

Start Date

June 13, 2025

Primary Completion Date

June 13, 2028

Completion Date

June 13, 2028

Last Updated

October 3, 2025

Enrollment

ESTIMATED participants

Conditions

Transcranial Magnetic Stimulation, RepetitiveDepression - Major Depressive Disorder

Interventions

repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol

DEVICE

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

RECRUITINGNA

Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression

NCT07422519

Depression - Major Depressive DisorderDepression Disorder+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.

Inclusion Criteria

Exclusion Criteria

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Fluoxetine on Emotional Experience (FLEX) Study

Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations

The Effect of PROSE or Scleral Lenses on Mental Health